A phase III trial, TRIUMPH-2, demonstrated that the investigational triple agonist retatrutide substantially improved body weight and glycemic control in adults with obesity and type 2 diabetes. At week 80, estimand data indicated average weight loss of 11.9% to 18.8% with retatrutide doses of 4 mg, 9 mg, and 12 mg, respectively, compared to 5.1% with placebo. Prior clinical trial data showed average body weight loss of 13.2% and 15.7% with high-dose semaglutide and tirzepatide, respectively. Another investigational therapy, combining eloralintide with tirzepatide, achieved a 23.3% weight loss in a type 2 diabetes population. Retatrutide’s efficacy estimand reached 20.8% weight loss. Significant reductions were observed in HbA1c, with up to 40% of participants achieving normoglycemia. Secondary endpoints showed improvements in waist circumference, triglycerides, non-HDL cholesterol, and high-sensitivity C-reactive protein. The trial, conducted across eight countries, involved 1,152 participants with a baseline BMI of 38.2 and HbA1c of 7.71%. Adverse events included gastrointestinal symptoms and hypotension. The study’s limitations included the absence of an active comparator arm and a lack of data on body composition.